共 50 条
Purine import into malaria parasites as a target for antimalarial drug development
被引:30
|作者:
Frame, I. J.
[1
]
Deniskin, Roman
[1
]
Arora, Avish
[1
]
Akabas, Myles H.
[1
,2
,3
]
机构:
[1] Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA
[2] Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA
[3] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA
来源:
关键词:
purines;
nucleoside transporter;
malaria;
drug development;
EQUILIBRATIVE NUCLEOSIDE TRANSPORTER;
PLASMODIUM-FALCIPARUM;
HUMAN-ERYTHROCYTES;
FUNCTIONAL-CHARACTERIZATION;
NUCLEOBASE TRANSPORT;
PLASMA-MEMBRANE;
S-6-(4-NITROBENZYL)-MERCAPTOPURINE RIBOSIDE;
SACCHAROMYCES-CEREVISIAE;
CYTOKININ BIOSYNTHESIS;
LEISHMANIA-DONOVANI;
D O I:
10.1111/nyas.12568
中图分类号:
R51 [传染病];
学科分类号:
100401 ;
摘要:
Infection with Plasmodium species parasites causes malaria. Plasmodium parasites are purine auxotrophs. In all life cycle stages, they require purines for RNA and DNA synthesis and other cellular metabolic processes. Purines are imported from the host erythrocyte by equilibrative nucleoside transporters (ENTs). They are processed via purine salvage pathway enzymes to form the required purine nucleotides. The Plasmodium falciparum genome encodes four putative ENTs (PfENT1-4). Genetic, biochemical, and physiologic evidence suggest that PfENT1 is the primary purine transporter supplying the purine salvage pathway. Protein mass spectrometry shows that PfENT1 is expressed in all parasite stages. PfENT1 knockout parasites are not viable in culture at purine concentrations found in human blood (<10 mu M). Thus, PfENT1 is a potential target for novel antimalarial drugs, but no PfENT1 inhibitors have been identified to test the hypothesis. Identifying inhibitors of PfENT1 is an essential step to validate PfENT1 as a potential antimalarial drug target.
引用
收藏
页码:19 / 28
页数:10
相关论文